

In the Claims

1-27 (canceled).

28 (currently amended). A method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:

- a.a) isolating said lipid rafts from said type of PrP^{Sc} cells; and
- b.b) immunizing an animal host by said isolated lipid rafts.

29 (previously presented). The method according to claim 28, wherein said type of PrP^{Sc} cells are either PrP^{Sc} sensitive cells or PrP^{Sc} resistant cells.

30 (currently amended). The method according to claim 28 further comprising:

- e.c) producing hybridomas from the immunized animal host, wherein said hybridomas produce monoclonal antibodies;
- d.d) selecting said monoclonal antibodies; and
- e.e) purifying said selected monoclonal antibodies.

31 (previously presented). The method according to claim 30, wherein said selecting further comprises selecting monoclonal antibodies that modulate conversion of PrP^C into PrP^{Sc} of said type of PrP^{Sc} sensitive cells.

32 (previously presented). The method according to claim 29, wherein said type of PrP^{Sc} sensitive cells are neuroblastoma cells.

33 (previously presented). The method according to claim 32, wherein said type of neuroblastoma cells are scN2a or N2A cells.

34 (previously presented). A method of identifying a lipid raft target comprising identifying an antigen that binds to antibodies that bind isolated lipid rafts from a type of PrP^{Sc} cells and determining a partial or full amino acid sequence or nucleic acid sequence of said antigen.

35 (currently amended). A composition of matter comprising:

- ~~(a) a hybridoma produced by method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:~~
 - ~~(i) isolating said lipid rafts from said type of PrP^{Sc} cells;~~
 - ~~(ii) immunizing an animal host by said isolated lipid rafts; and~~
 - ~~(iii) producing hybridomas from the immunized animal host, wherein said hybridomas produce monoclonal antibodies;~~
- (a) the hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601;
- (b) the hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901;
- (c) the hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603;
- (d) an isolated antibody or antigen binding fragment thereof generated by a hybridoma produced by method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:
 - (i) isolating said lipid rafts from said type of PrP^{Sc} cells;
 - (ii) immunizing an animal host by said isolated lipid rafts;
 - (iii) producing hybridomas from the immunized animal host; and
 - (iv) isolating the antibody produced by said hybridoma;
- (e) the monoclonal antibody generated by hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601;
- (f) the monoclonal antibody generated by hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901;

- (gh) the monoclonal antibody generated by hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603;
- (hi) an antigen, or specific portion thereof, that binds to:
 - (A) an antibody or antigen binding fragment thereof generated by a hybridoma produced by method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:
 - (i) isolating said lipid rafts from said type of PrP^{Sc} cells;
 - (ii) immunizing an animal host by said isolated lipid rafts;
 - (iii) producing hybridomas from the immunized animal host; and
 - (iv) isolating the antibody produced by said hybridoma;
 - (B) the monoclonal antibody generated by hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601;
 - (C) the monoclonal antibody generated by hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901; or
 - (D) the monoclonal antibody generated by hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603;
- (ij) an isolated antibody, monoclonal antibody, chimeric antibody, fully humanized antibody, anti-anti-ID antibody or fragment thereof being capable of specifically binding an antigen that binds to:
 - (A) an antibody or antigen binding fragment thereof generated by a hybridoma produced by ~~method~~ a method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:
 - (i) isolating said lipid rafts from said type of PrP^{Sc} cells;
 - (ii) immunizing an animal host by said isolated lipid rafts;
 - (iii) producing hybridomas from the immunized animal host; and
 - (iv) isolating the antibody produced by said hybridoma;
 - (B) the monoclonal antibody generated by hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601;

- (C) the monoclonal antibody generated by hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901; or
- (D) the monoclonal antibody generated by hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603; or
- (jk) a pharmaceutical composition comprising a pharmaceutically acceptable carrier and:
 - (A) an antibody or antigen binding fragment thereof generated by a hybridoma produced by ~~method~~ a method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:
 - (i) isolating said lipid rafts from said type of PrP^{Sc} cells;
 - (ii) immunizing an animal host by said isolated lipid rafts;
 - (iii) producing hybridomas from the immunized animal host; and
 - (iv) isolating the antibody produced by said hybridoma;
 - (B) the monoclonal antibody generated by hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601;
 - (C) the monoclonal antibody generated by hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901;
 - (D) the monoclonal antibody generated by hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603; or
 - (E) an isolated antibody, monoclonal antibody, chimeric antibody, fully humanized antibody, anti-anti-ID antibody or fragment thereof being capable of specifically binding an antigen that binds to:
 - (a) an antibody or antigen binding fragment thereof generated by a hybridoma produced by ~~method~~ a method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:
 - (i) isolating said lipid rafts from said type of PrP^{Sc} cells;
 - (ii) immunizing an animal host by said isolated lipid rafts;
 - (iii) producing hybridomas from the immunized animal host; and
 - (iv) isolating the antibody produced by said hybridoma;

- (b) the monoclonal antibody generated by hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601;
- (c) the monoclonal antibody generated by hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901; or
- (d) the monoclonal antibody generated by hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603.

36 (previously presented). The composition of matter according to claim 35, wherein said hybridoma produces monoclonal antibodies that modulate conversion of PrP^C into PrP^{Sc} of said type of PrP^{Sc} sensitive cells.

37 (previously presented). The composition of matter according to claim 35, wherein said hybridoma is produced by immunizing an animal host with neuroblastoma cells.

38 (previously presented). The composition of matter according to claim 37, wherein said hybridoma is produced by immunizing an animal host with neuroblastoma cells selected from scN2a or N2A cells.

39 (currently amended). The composition of matter according to claim 35, wherein said pharmaceutical composition comprises an antibody or antibody fragment ~~is~~ that is further capable of regulating a biochemical activity of said antigen or a specific portion thereof.

40-45 (canceled).

46 (new). A hybridoma produced by the method according to claim 31.

47 (new). A hybridoma produced by the method according to claim 33.

48 (new). The composition of matter according to claim 35, wherein said composition of matter comprises the hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601.

49 (new). The composition of matter according to claim 35, wherein said composition of matter comprises the hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901.

50 (new). The composition of matter according to claim 35, wherein said composition of matter comprises the hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603.

51 (new). The composition of matter according to claim 35, wherein said composition of matter comprises an antibody or fragment thereof produced by a method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:

- (i) isolating said lipid rafts from said type of PrP^{Sc} cells;
- (ii) immunizing an animal host by said isolated lipid rafts;
- (iii) producing hybridomas from the immunized animal host; and
- (iv) isolating the antibody produced by said hybridoma.

52 (new). The composition of matter according to claim 35, wherein said composition of matter comprises the monoclonal antibody produced by hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601.

53 (new). The composition of matter according to claim 35, wherein said composition of matter comprises the monoclonal antibody produced by hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901.

54 (new). The composition of matter according to claim 35, wherein said composition of matter comprises the monoclonal antibody produced by hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603 according to claim 11.

55 (new). The composition of matter according to claim 35, wherein said composition of matter comprises an antigen or a specific portion thereof that binds to the antibody or a fragment thereof produced by a method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:

- (i) isolating said lipid rafts from said type of PrP^{Sc} cells;
- (ii) immunizing an animal host by said isolated lipid rafts;
- (iii) producing hybridomas from the immunized animal host; and
- (iv) isolating the antibody produced by said hybridoma.

56 (new). The composition of matter according to claim 35, wherein said composition of matter comprises an antigen or a specific portion thereof that binds to:

- (a) the monoclonal antibody generated by hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601;
- (b) the monoclonal antibody generated by hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901; or
- (c) the monoclonal antibody generated by hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603.

57 (new). An antibody, monoclonal antibody, chimeric antibody, fully humanized antibody, anti-anti-ID antibody or fragment thereof being capable of specifically binding said antigen or a specific portion thereof according to claim 56.

58 (new). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and:

- (a) an antibody or antigen binding fragment thereof generated by a hybridoma produced by a method for generating an antibody against a lipid raft target associated with a type of PrP^{Sc} cells, comprising:
 - (i) isolating said lipid rafts from said type of PrP^{Sc} cells;
 - (ii) immunizing an animal host by said isolated lipid rafts;
 - (iii) producing hybridomas from the immunized animal host; and
 - (iv) isolating the antibody produced by said hybridoma;
- (b) the monoclonal antibody generated by hybridoma clone designated #51 deposited at the ECACC under Provisional Accession No. 05021601;
- (c) the monoclonal antibody generated by hybridoma clone designated #57 deposited at the ECACC under Provisional Accession No. 05030901; or
- (d) the monoclonal antibody generated by hybridoma clone designated #245 deposited at the ECACC under Provisional Accession No. 05021603.